Nature Article Highlights AlbuVoid™ in Autophagy and Cancer Study

News Release

Nature Article Highlights AlbuVoid™ in Autophagy and Cancer Study


MONMOUTH JUNCTION, NJ, December 13, 2018 -- Biotech Support Group reports on a new research report which highlights the simplicity and efficiency of their albumin depletion sample preparation technology as an enrichment step for mouse serum LC-MS proteomic analysis. The citation is:


Poillet-Perez, Laura, et al. "Autophagy maintains tumour growth through circulating arginine." Nature (2018): 1.


Autophagy is a cellular mechanism which captures intracellular components and delivers them to lysosomes, where they are degraded and recycled, helping cells survive during times of starvation. One in vivo model to study autophagy is whole-body deletion of the essential autophagy gene Atg7 in adult mice which causes a systemic metabolic defect that manifests as starvation intolerance. In order to measure the systemic proteomic response of such deletion in this study, AlbuVoid™ was chosen as one method to remove albumin and enrich the low abundance proteomes from serum. The article states “…AlbuVoid (Biotech Support Group) was used to deplete albumin…”. This was done for the purpose of estimating differential protein abundances by LC-MS derived spectral counts. The serum proteomic investigation identified arginine-degrading enzyme arginase I (ARG1) in the circulation of Atg7-deficient hosts as one of several differentially identified proteins. Such evidence helped the authors’ conclude that defective autophagy in the host leads to the release of ARG1 from the liver and the degradation of circulating arginine, which is essential for tumour growth; thus identifying a metabolic vulnerability of cancer.


I are very pleased to see that AlbuVoid™ was used for the mouse serum LC-MS analysis. Although only one piece of this very interesting autophagy puzzle, it nevertheless helped provide evidence for a metabolic vulnerability in tumors” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.


For more information on AlbuVoid™, go to: http://www.biotechsupportgroup.com/AlbuVoid-Albumin-Depletion-and-Low-Abundance-p/avk.htm


For more information on the BSG complete line of Albumin & IgG Removal products, visit: https://www.biotechsupportgroup.com/Articles.asp?ID=451


About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com.


Contact:
Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com